Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1993 Feb;67(2):358–361. doi: 10.1038/bjc.1993.65

Uptake and retention of estramustine and the presence of estramustine binding protein in malignant brain tumours in humans.

A T Bergenheim 1, P O Gunnarsson 1, K Edman 1, E von Schoultz 1, M I Hariz 1, R Henriksson 1
PMCID: PMC1968176  PMID: 8431366

Abstract

Estraumustine phosphate (EMP), a cytotoxic drug used in the treatment of prostatic carcinoma, has been shown to exert cytotoxic effects on glioma cells in vitro. The drug uptake is assumed to depend on a specific estramustine binding protein (EMBP). One of the main difficulties in achieving cytotoxic effect in malignant brain tumours is believed to be due to the poor penetration of cytotoxic drugs into tumour tissue. In patients with malignant supratentorial brain tumours we have analysed the uptake of EMP metabolites in tumour tissue after oral administration and demonstrated EMBP in the same tissue specimens. Sixteen patients were given 280 mg EMP orally 14 h prior to surgery. Specimens from brain tumour tissue, cystic fluid, and serum were collected during surgery. Using gas chromatography the metabolites of EMP, estramustine (EaM) and estromustine (EoM), were quantified, EMBP was demonstrated by immunohistochemistry. The mean concentrations of EaM and EoM, expressed in ng g-1, were 60.3 and 38.4 in tumour tissue and 3.5 and 56.3 in serum, respectively. An accumulation of EaM in tumour tissue was found with a mean concentration gradient of 16.1 versus serum, while the gradient for EoM was 0.76. EMBP was demonstrated with a high degree of staining in all but one tumour. The high concentrations of EaM and EoM found in malignant brain tumour tissue correspond to potentially cytotoxic levels. The present results as well as the earlier in vitro demonstrated cytotoxic effects on glioma cells strengthen the possibility of a therapeutic effect of EMP in the treatment of malignant brain tumours.

Full text

PDF
358

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andersson S. B., Gunnarsson P. O., Nilsson T., Forshell G. P. Metabolism of estramustine phosphate (Estracyt) in patients with prostatic carcinoma. Eur J Drug Metab Pharmacokinet. 1981;6(2):149–154. doi: 10.1007/BF03189482. [DOI] [PubMed] [Google Scholar]
  2. Andersson S. B., Lundgren R., Svensson L. Gas chromatographic determination of four metabolites of estramustine phosphate in plasma. Acta Pharm Suec. 1982;19(1):1–10. [PubMed] [Google Scholar]
  3. Bergh J., Björk P., Westlin J. E., Nilsson S. Expression of an estramustine-binding associated protein in human lung cancer cell lines. Cancer Res. 1988 Aug 15;48(16):4615–4619. [PubMed] [Google Scholar]
  4. Caceres A., Binder L. I., Payne M. R., Bender P., Rebhun L., Steward O. Differential subcellular localization of tubulin and the microtubule-associated protein MAP2 in brain tissue as revealed by immunocytochemistry with monoclonal hybridoma antibodies. J Neurosci. 1984 Feb;4(2):394–410. doi: 10.1523/JNEUROSCI.04-02-00394.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Flüchter S. H., Nelde H. J., Björk P., Müntzing J., Bichler K. H. Effect of treatment on the expression of estramustine-binding protein (EMBP) in prostatic cancer patients: an immunohistochemical study. Prostate. 1989;14(1):27–43. doi: 10.1002/pros.2990140105. [DOI] [PubMed] [Google Scholar]
  6. Forsgren B., Björk P., Carlström K., Gustafsson J. A., Pousette A., Högberg B. Purification and distribution of a major protein in rat prostate that binds estramustine, a nitrogen mustard derivative of estradiol-17 beta. Proc Natl Acad Sci U S A. 1979 Jul;76(7):3149–3153. doi: 10.1073/pnas.76.7.3149. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Forsgren B., Gustafsson J. A., Pousette A., Högberg B. Binding characteristics of a major protein in rat ventral prostate cytosol that interacts with estramustine, a nitrogen mustard derivative of 17 beta-estradiol. Cancer Res. 1979 Dec;39(12):5155–5164. [PubMed] [Google Scholar]
  8. Fridén B., Wallin M., Deinum J., Prasad V., Luduena R. Effect of estramustine phosphate on the assembly of trypsin-treated microtubules and microtubules reconstituted from purified tubulin with either tau, MAP2, or the tubulin-binding fragment of MAP2. Arch Biochem Biophys. 1987 Aug 15;257(1):123–130. doi: 10.1016/0003-9861(87)90550-9. [DOI] [PubMed] [Google Scholar]
  9. Gunnarsson P. O., Andersson S. B., Johansson S. A., Nilsson T., Plym-Forshell G. Pharmacokinetics of estramustine phosphate (Estracyt) in prostatic cancer patients. Eur J Clin Pharmacol. 1984;26(1):113–119. doi: 10.1007/BF00546718. [DOI] [PubMed] [Google Scholar]
  10. Gunnarsson P. O., Davidsson T., Andersson S. B., Backman C., Johansson S. A. Impairment of estramustine phosphate absorption by concurrent intake of milk and food. Eur J Clin Pharmacol. 1990;38(2):189–193. doi: 10.1007/BF00265983. [DOI] [PubMed] [Google Scholar]
  11. Hartley-Asp B. Estramustine-induced mitotic arrest in two human prostatic carcinoma cell lines DU 145 and PC-3. Prostate. 1984;5(1):93–100. doi: 10.1002/pros.2990050109. [DOI] [PubMed] [Google Scholar]
  12. Hsu S. M., Raine L., Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem. 1981 Apr;29(4):577–580. doi: 10.1177/29.4.6166661. [DOI] [PubMed] [Google Scholar]
  13. Kruse E., Hartley-Asp B. Uptake and metabolism of estramustine in the Dunning R3327H tumour. In Vivo. 1988 Nov-Dec;2(6):371–375. [PubMed] [Google Scholar]
  14. Kruse E., Johansson S. A., Hartley-Asp B., Gunnarsson P. O. Distribution and metabolism of estramustine in HeLa cells and the human prostatic tumour cell line 1013L. Biochem Pharmacol. 1988 Aug 15;37(16):3161–3167. doi: 10.1016/0006-2952(88)90315-2. [DOI] [PubMed] [Google Scholar]
  15. Norlén B. J., Andersson S. B., Björk P., Gunnarsson P. O., Fritjofsson A. Uptake of estramustine phosphate (estracyt) metabolites in prostatic cancer. J Urol. 1988 Nov;140(5):1058–1062. doi: 10.1016/s0022-5347(17)41926-4. [DOI] [PubMed] [Google Scholar]
  16. Stearns M. E., Tew K. D. Estramustine binds MAP-2 to inhibit microtubule assembly in vitro. J Cell Sci. 1988 Mar;89(Pt 3):331–342. doi: 10.1242/jcs.89.3.331. [DOI] [PubMed] [Google Scholar]
  17. Vallee R. B. A taxol-dependent procedure for the isolation of microtubules and microtubule-associated proteins (MAPs). J Cell Biol. 1982 Feb;92(2):435–442. doi: 10.1083/jcb.92.2.435. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Whittle I. R., MacPherson J. S., Miller J. D., Smyth J. F. The disposition of TCNU (tauromustine) in human malignant glioma: pharmacokinetic studies and clinical implications. J Neurosurg. 1990 May;72(5):721–725. doi: 10.3171/jns.1990.72.5.0721. [DOI] [PubMed] [Google Scholar]
  19. von Holst H., Knochenhauer E., Blomgren H., Collins V. P., Ehn L., Lindquist M., Norén G., Peterson C. Uptake of adriamycin in tumour and surrounding brain tissue in patients with malignant gliomas. Acta Neurochir (Wien) 1990;104(1-2):13–16. doi: 10.1007/BF01842886. [DOI] [PubMed] [Google Scholar]
  20. von Schoultz E., Bergenheim T., Grankvist K., Henriksson R. Estramustine binding protein in human brain-tumor tissue. J Neurosurg. 1991 Jun;74(6):962–964. doi: 10.3171/jns.1991.74.6.0962. [DOI] [PubMed] [Google Scholar]
  21. von Schoultz E., Gunnarsson P. O., Henriksson R. Uptake, metabolism and antiproliferative effect of estramustine phosphate in human glioma cell lines. Anticancer Res. 1989 Nov-Dec;9(6):1713–1716. [PubMed] [Google Scholar]
  22. von Schoultz E., Lundblad D., Bergh J., Grankvist K., Henriksson R. Estramustine binding protein and anti-proliferative effect of estramustine in human glioma cell lines. Br J Cancer. 1988 Sep;58(3):326–329. doi: 10.1038/bjc.1988.212. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. von Schoultz E., Lundgren E., Henriksson R. Effects of estramustine and its constituents on human malignant glioma cells. Anticancer Res. 1990 May-Jun;10(3):693–696. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES